

Page 22

Line 10, after "Trp" insert --(SEQ ID NO:12)--

Line 12, after "Trp" insert --(SEQ ID NO:13)--

Page 46

Line 19, change "(710-731:" to --(Residues 710-730 of SEQ ID NO:3--

Page 49

Line 2, after "Trp" insert --(SEQ ID NO:12)--

Line 5, after "Trp" insert --(SEQ ID NO:13)--

Page 58

Line 1, after "ALTLPFSGERPRRID" insert --(residues 92-106 of SEQ ID NO:3)--

Line 1, after "SPEDER" insert --(residues 710 to 731 of SEQ ID NO:3)--

Line 25, after "Asp-Leu" insert --(SEQ ID NO:14)--

Please delete pages 66 through 88 of the specification containing the Sequence Listing.
Please renumber the remaining pages of the specification, beginning with the claims,
consecutively from page 66 of the specification. Please insert the Substitute Sequence Listing
enclosed herewith immediately after the abstract.

IN THE CLAIMS:

Please cancel claim 15 without prejudice or disclaimer of the subject matter contained
therein.

Please amend the following claims:

Q2 Claim 8 (Amended) An expression plasmid which expresses either a gene of any one of claims [1 to 3 and] 1, 2, 3, 5, or the DNA of claim 7.

Claim 11 (Amended)

Line 2, delete "or 6"

Claim 14 (Amended) An antisense nucleotide, or chemically modified variant thereof, which is directed against a segment of at least eight or more bases of a gene of any one of claims [1 to 3, or of] 1, 2, 3 or the DNA of claim 7.

Claim 16 (Amended)

Line 1, delete "of claim 4 or 6, or"

Q3 66030-08748260
Claim 17 (Amended) A pharmaceutical [agent] composition comprising, as an active ingredient, a gene of any one of claims [1 to 3 and 5,] 1, 2, 3, 5, or the DNA of claim 7[, protein of claim 4 or 6, a peptide of any one of claims 11 to 13, an antisense nucleotide or chemically modified variant thereof of claim 14 or 15] or an antibody of claim 16]; and a pharmaceutically acceptable carrier.

Claim 18 (Amended) A method of screening for Semaphorin W antagonists, [characterized in that it employs] comprising contacting a protein of claim 4 with a sample to be screened for Semaphorin W antagonists.

Claim 20 (Amended)

Line 2, delete ", a peptide of any one of claims 11 to 13 or an antibody of claim 16"

Q4
Claim 21 (Amended) A CNS-neuron regeneration promoter[, characterized in that it contains] which contains at least one of antisense nucleotides or chemically modified variants thereof, of claim 14 [or 15, or Semaphorin W antagonists of claim 19 or 20].

Claim 22 (Amended)

Line 2, change "characterized in that it contains" to --which comprises--

Claim 23 (Amended)

Line 2, change "3 and 5, or" to --3, 5, or the--

Please add the following new claims:

05
--24. A peptide comprising a segment of at least six or more amino acids of a protein of claim 6.

25. A pharmaceutical composition comprising, as an active ingredient, a protein of claim 4; and a pharmaceutically acceptable carrier.

26. A pharmaceutical composition comprising, as an active ingredient, a protein of claim 6; and a pharmaceutically acceptable carrier.

27. A pharmaceutical composition comprising, as an active ingredient, a peptide of any one of claims 11 to 13; and a pharmaceutically acceptable carrier.

28. A pharmaceutical composition comprising, as an active ingredient, an antisense nucleotide or chemically modified variant thereof of claim 14; and a pharmaceutically acceptable carrier.

29. A pharmaceutical composition comprising, as an active ingredient, an antibody of claim 16; and a pharmaceutically acceptable carrier.

30. An antibody against a protein of claim 4.

31. An antibody against a protein of claim 6.